EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 25 / No 12 (Décembre 2009) Med Sci (Paris), 25 12 (2009) 1145-1148 References
Free Access
Issue
Med Sci (Paris)
Volume 25, Number 12, Décembre 2009
Anticorps monoclonaux en thérapeutique
Page(s) 1145 - 1148
Section III - Un futur en développement
DOI https://doi.org/10.1051/medsci/200925121145
Published online 15 December 2009
  1. Inglesby TV, O’Toole T, Henderson DA, et al. Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA 2002; 287 : 2236–52. [Google Scholar]
  2. Binder P, Lepick O. Les armes biologiques. Paris : PUF, 2001. [Google Scholar]
  3. Mayor S. UK doctors warned after ricin poison found in police raid. Br Med J 2003; 326 : 126. [Google Scholar]
  4. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates ? Nat Rev Drug Discov 2004; 3 : 711–5. [Google Scholar]
  5. Sawada-Hirai R, Jiang I, Wang F, et al. Human anti-anthrax protective antigen neutralizing monoclonal antibodies derived from donors vaccinated with anthrax vaccine adsorbed. J Immune Based Ther Vaccines 2004; 2 : 5. [Google Scholar]
  6. Little SF, Leppla SH, Cora E. Production and characterization of monoclonal antibodies to the protective antigen component of Bacillus anthracis toxin. Infect Immun 1988; 56 : 1807–13. [Google Scholar]
  7. Little SF, Ivins BE, Fellows PF, Friedlander AM. Passive protection by polyclonal antibodies against Bacillus anthracis infection in guinea pigs. Infect Immun 1997; 65 : 5171–5. [Google Scholar]
  8. Wild MA, Xin H, Maruyama T, et al. Human antibodies from immunized donors are protective against anthrax toxin in vivo. Nat Biotechnol 2003; 21 : 1305–6. [Google Scholar]
  9. Mohamed N, Clagett M, Li J, et al. A high-affinity monoclonal antibody to anthrax protective antigen passively protects rabbits before and after aerosolized Bacillus anthracis spore challenge. Infect Immun 2005; 73 : 795–802. [Google Scholar]
  10. Wang F, Ruther P, Jiang I, et al. Human monoclonal antibodies that neutralize anthrax toxin by inhibiting heptamer assembly. Hum Antibodies 2004; 13 : 105–10. [Google Scholar]
  11. Laffly E, Danjou L, Condemine F, et al. Selection of a macaque Fab with framework regions like those in humans, high affinity, and ability to neutralize the protective antigen (PA) of Bacillus anthracis by binding to the segment of PA between residues 686 and 694. Antimicrob Agents Chemother 2005; 49 : 3414–20. [Google Scholar]
  12. Pelat T, Hust M, Laffly E, et al. High-affinity, human antibody-like antibody fragment (single-chain variable fragment) neutralizing the lethal factor (LF) of Bacillus anthracis by inhibiting protective antigen-LF complex formation. Antimicrob Agents Chemother 2007; 51 : 2758–64. [Google Scholar]
  13. Baillie LSL, Quinn C, Swann P, et al. Expert Consultation on Monoclonal Antibodies for Anthrax rPA. 2003. Online : http://www3.niaid.nih.gov/biodefense/resaerch/products.htm#5. [Google Scholar]
  14. Jones SM, Ellis JF, Russell P, et al. Passive protection against Burkholderia pseudomallei infection in mice by monoclonal antibodies against capsular polysaccharide, lipopolysaccharide or proteins. J Med Microbiol 2002; 51 : 1055–62. [Google Scholar]
  15. Hill J, Eyles JE, Elvin SJ, et al. Administration of antibody to the lung protects mice against pneumonic plague. Infect Immun 2006; 74 : 3068–70. [Google Scholar]
  16. Chen Z, Earl P, Americo J, et al. Chimpanzee/human mAbs to vaccinia virus B5 protein neutralize vaccinia and smallpox viruses and protect mice against vaccinia virus. Proc Natl Acad Sci USA 2006; 103 : 1882–7. [Google Scholar]
  17. Su HP, Golden JW, Gittis AG, et al. Structural basis for the binding of the neutralizing antibody, 7D11, to the poxvirus L1 protein. Virology 2007; 368 : 331–41. [Google Scholar]
  18. Arnon SS, Schechter R, Inglesby TV, et al. Botulinum toxin as a biological weapon: medical and public health management. JAMA 2001; 285 : 1059–70. [Google Scholar]
  19. Foxwell BM, Detre SI, Donovan TA, Thorpe PE. The use of anti-ricin antibodies to protect mice intoxicated with ricin. Toxicology 1985; 34 : 79–88. [Google Scholar]
  20. Dubel S. Handbook of therapeutic antibodies. Weinheim : Wiley-VCH, 2007. [Google Scholar]
  21. Amersdorfer P, Wong C, Smith T, et al. Genetic and immunological comparison of anti-botulinum type A antibodies from immune and non-immune human phage libraries.Vaccine 2002; 20 : 1640–8. [Google Scholar]
  22. Chen Z, Earl P, Americo J, et al. Characterization of chimpanzee/human monoclonal antibodies to vaccinia virus A33 glycoprotein and its variola virus homolog in vitro and in a vaccinia virus mouse protection model. J Virol 2007; 81 : 8989–95. [Google Scholar]
  23. Choi TK, Hollenbach PW, Pearson BE, et al. Transgenic mice containing a human heavy chain immunoglobulin gene fragment cloned in a yeast artificial chromosome. Nat Genet 1993; 4 : 117–23. [Google Scholar]
  24. Fishwild DM, O’Donnell SL, Bengoechea T, et al. High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice. Nat Biotechnol 1996; 14 : 845–51. [Google Scholar]
  25. Bellet D, Pecking A, Dangles-Marie V. XenoMouse : un tour de force pour l’obtention d’anticorps humains chez la souris. Med Sci (Paris) 2008 24 : 903–5. [Google Scholar]
  26. Barbas CF. Phage display: a laboratory manual. New York : Cold Spring Harbor Laboratory Press, 2001. [Google Scholar]
  27. Brochet X, Lefranc MP, Giudicelli V. IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis. Nucleic Acids Res 2008 36 : W503–8. [Google Scholar]
  28. Whitelegg NR, Rees AR. WAM: an improved algorithm for modelling antibodies on the WEB. Protein Eng 2000; 13 : 819–24. [Google Scholar]
  29. Pelat T, Bedouelle H, Rees AR, et al. Germline humanization of a non-human primate antibody that neutralizes the anthrax toxin, by in vitro and in silico engineering. J Mol Biol 2008; 384 : 1400–7. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.